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Abstract: Disease-focused philanthropic organizations play an increasing role in the strategy and conduct of biomedical 
research, with many focusing on drug development for specific diseases and patient populations. More and more they 
not only provide resources and expertise, but also take active part managing the strategy and objectives of targeted re-
search programs, using approaches such as venture philanthropy. Many also lead and participate in public–private part-
nerships. One example is the partnership between the Polycystic Kidney Disease (PKD) Foundation and the Critical 
Path Institute (C-Path) which brings together several pharmaceutical companies and academic institutions to develop 
new broadly-used biomarkers. Another case is the partnership between JDRF (formerly known as the Juvenile Diabetes 
Research Foundation) and the Innovative Medicines Initiative (IMI), involving financial support of the IMIDIA project 
(Innovative Medicines Initiative for Diabetes) which is focused on improving beta-cell function and identifying bio-
markers for diabetes treatment monitoring. These examples show that in addition to providing financial support and 
expertise, philanthropic foundations are also in a unique position to coordinate the patient and research communities to 
enable and accelerate specific medicines development projects. 
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1. Introduction 
ranslational biomedical research has always 
depended on collaborations based on resources 
and expertise brought by each partner to ad-
vance an initial finding to clinical application. Tradi-
tionally, many of these partnerships focused on ad-
vancing a single product or were extracurricular activi-
ties that evaluated early-stage concepts. While these 
efforts continue to dominate the biomedical landscape, 
the past decade has also witnessed the emergence of 
over 400 research consortia. This model of partnership 
temporarily combines the resources and expertise of 
multiple stakeholders to develop a shared tool or asset, 
with an aim to advance the efforts of its partners and 
those of the broader scientific community[1].  
Research consortia aim to reduce the risk of inno-
vating methods for discovering and manufacturing 
medical products, as well as standardize processes in a 
highly regulated industry[2]. At first glance, the mis-
sion statements of government agencies, academic 
research institutions, and private-sector drug develop-
ment would seem to have more differences than simi-
larities. However, the multitude of drug development 
partnerships indicates the diversity of synergies leve-
raged to address each stakeholder’s unique vulnerabi-
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lities. For example, with 64% of global spending into 
drug development coming from only 20 companies[3], 
the entire biopharmaceutical sector is sensitive to 
changes in regulatory policy and market forces that 
affect a single company, in addition to the overall 
scientific and clinical challenges for developing drugs. 
At the same time, regulatory agencies often do not 
have the resources to stay ahead of drug development 
science, finding themselves ill-prepared to evaluate 
the safety and efficacy of product candidates based on 
next-generation technologies. In addition to regulating 
medical products, other government biomedical agen-
cies play multiple roles to advance society through the 
preservation of public health, advancement of eco-
nomic competitiveness, and sustaining innovation. As 
shown by the recent Ebola outbreak and continuing 
challenges such as Alzheimer’s disease, government 
agencies lack the capability to single-handedly ad-
vance drug and vaccine development against complex 
diseases and are increasingly focusing their resources 
to catalyze public–private partnerships that expand the 
impact of their limited taxpayer dollars, rather than 
finding ways to integrate independent and individual-
ly-funded research efforts[4−6].  
2. The Role of Philanthropic Foundations 
Another biomedical research stakeholder with in-
creasing influence is the disease-focused philanthropic 
foundation. With over 200,000 philanthropies operat-
ing in Europe and the US, the majority of these 
not-for-profit organizations derive their finances from 
donated personal assets or fundraising. Most are dri-
ven by altruism and a sense of social responsibility 
across a wide field of interests—two-thirds have a 
health-related focus[7]—and distribute their funds as 
charitable gifts. A subset of philanthropies focus on 
advancing drug development for specific diseases and 
patient populations[8], many of which leverage their 
resources and expertise through an investment ap-
proach known as venture philanthropy[9]. Instead of 
providing a grant or gift to a researcher, this model of 
impact investing gives a philanthropy the ability to 
proactively manage the strategy and scientific objec-
tives of a research program in collaboration with their 
partner. These investments often include conditions 
for financial recovery to ensure sustainability and 
support of further research in their disease or condi-
tion of interest[10]. 
In addition to directly supporting a single research 
organization, many disease-focused venture philanth-
ropies further diversify their portfolio by leveraging 
public–private partnerships to broadly advance drug 
development. Non-profit foundations are considered 
as neutral parties that focus only on improving the 
lives of a specific patient population, regardless of a 
specific company or product, and can serve as 
safe-harbor conveners between multiple drug develop-
ment companies and government regulators. The 
scope of consortia that involve participation of phi-
lanthropies cover the whole research and development 
process (Table 1), all with the assumption that new 
and broadly-usable tools would catalyze entry of mul-
tiple companies into a specific and oftentimes neg-
lected disease area. For example, diagnostic/prog-
nostic biomarkers that can be used to stage a disease 
or track its progression are often not available or are 
poorly-validated, an absence of evidence that creates a 
scientific hurdle and unclear regulatory pathway. 
Consortia which convene regulatory scientists with 
companies that use similar approaches for developing 
drugs act as a forum for open collaboration, often to 
develop standardized and non-product-specific tools 
that aid regulatory evaluation. By combining the col-
lective knowledge of their internal staff and funded 
investigators with the resources and expertise of the 
broader research community, foundations also have a 
unique position to lead clinical biomarker studies that 
address drug development needs, designed in a man-
ner sensitive to the lifestyle challenges of their patient 
populations. Foundations can also coordinate patient 
populations who already support their mission to 
power and execute longitudinal natural history studies, 
often in concert with industry supporters who lack the 
resources and expertise to conduct these essential stu-
dies on their own. As public–private partnerships, the 
data generated by these consortia are often made 
available to the wider scientific community. The out-
come of these opportunities is not to improve the 
chance of success for a single company, but to bring 
benefit to a whole patient population. 
3. Polycystic Kidney Disease Foundation and C-Path 
In many instances, foundations are responsible for 
setting the scientific agenda and convening stakehold-
ers to further develop and initiate a research consor-
tium. For example, one strategy for the US-based Po-
lycystic Kidney Disease (PKD) Foundation is to de-
velop shared tools such as surrogate endpoint meas-
ures to incentivize industry investment into novel 
treatment options for autosomal dominant polycystic 
kidney disease (ADPKD)[11]. This genetic disease is 
suffered by millions across the globe with more than 
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Table 1. Examples of drug development consortia with philanthropic stakeholders 
Consortium Philanthropy Management Organization Purpose 
Critical Path to TB Drug 
Regimens 
Bill and Melinda Gates Foundation, 
TB Alliance Critical Path Institute 
Develop data standards, qualify biomarkers 
for regulatory application, develop natural 
history models 
Multiple Sclerosis Outcome 
Assessments Consortium National Multiple Sclerosis Society Critical Path Institute 
Qualification of clinician-reported outcome 
(ClinRO) assessments 
Polycystic Kidney Disease 
Outcomes Consortium 
Polycystic Kidney Disease  
Foundation Critical Path Institute 
Develop data standards and qualify imaging 
biomarkers for regulatory application 
Accelerating Medicines 
Partnership: Rheumatoid 
Arthritis and Lupus 
Arthritis Foundation, Lupus  
Foundation of America, Alliance for 
Lupus Research, Rheumatology 
Research Foundation 
Foundation for the National 
Institutes of Health 
Develop biomarkers for diagnosis and drug 
development 
 
 
Alzheimer’s Disease  
Neuroimaging Initiative 
Alzheimer’s Association, Alzhei-
mer’s Drug Discovery Foundation 
Foundation for the National 
Institutes of Health 
Develop biomarkers that diagnose patients 
with Alzheimer’s disease and monitor disease 
progression 
The Lung Cancer Master 
Protocol Friends of Cancer Research 
Develop and implement a clinical trial model 
that uses a multi-drug, targeted screening 
approach to match patients  
European Autism  
Interventions Autism Speaks 
Innovative Medicines  
Initiative 
Create validated cellular assays, animal mod-
els, new fMRI methods with dedicated analy-
sis techniques, and new PET radioligands, as 
well as new genetic and proteomic biomarkers 
for patient-segmentation or individual re-
sponse prediction 
Biomarkers for Type 1  
Diabetes and Retinal Diseases 
JDRF, Leona M. and Harry B. 
Helmsley Charitable Trust 
Innovative Medicines  
Initiative 
Develop predictive biomarkers of disease 
progression 
Pertussis Vaccination  
Research Bill and Melinda Gates Foundation 
Innovative Medicines  
Initiative 
Develop biomarkers indicating protective 
immunity to pertussis 
Parkinson’s Progression 
Markers Initiative Michael J. Fox Foundation for Parkinson’s Research  
Develop biomarkers for Parkinson’s disease 
progression 
 
50% developing kidney failure by the age of 50. With 
the exception of one recently approved treatment, no 
other treatment has been proven to prevent or delay 
the progression of ADPKD. The accepted regulatory 
endpoint is estimated glomerular filtration rate 
(eGFR), which stays largely stable for most of the 
patient’s life even though the kidneys continue to 
grow inexorably; the PKD Foundation identified a 
need to develop a more rigorous biomarker given the 
weakness of this gold standard. The PKD Outcome 
Consortium, formed between the foundation with the 
non-profit Critical Path Institute (C-Path) and several 
pharmaceutical companies and academic institutions, 
focused on demonstrating total kidney volume as a 
new prognostic biomarker, for use as inclusion crite-
rion in clinical trials to identify patients likely to show 
clinically-relevant decline in kidney function during 
the duration of a trial[12]. Through the consortium, data 
from patient registries and longitudinal studies were 
contributed, standardized, and pooled to develop a 
quantitative model in support of the intended use of 
this new biomarker. The final deliverable of the con-
sortium, evidence that aims to support qualification of 
this biomarker, was submitted in March 2014 to both 
the Food and Drug Administration (US FDA) and the 
European Medicines Agency (EMA) for their consid-
eration.  
4. JDRF and IMI 
Another example of how a disease-based foundation 
provides leadership, funding and influence to facilitate 
advancement in drug development is provided by 
JDRF (formerly known as the Juvenile Diabetes Re-
search Foundation), the largest non-profit foundation 
and funder of type 1 diabetes (T1D) research. The 
foundation established a relationship with the Innova-
tive Medicines Initiative (IMI), a joint undertaking 
between the European Union and the European Phar-
maceutical Industry Association (EFPIA) that creates 
and manages drug development consortia. In 2012, 
JDRF began a partnership with the IMI program, 
IMIDIA (Innovative Medicines Initiative for Diabetes), 
investing around €1,000,000 to better understand pan-
creas beta-cell biology and the natural mechanisms 
that control beta cell mass and function. JDRF also 
contributed more than €350,000 to the IMI SUMMIT 
(Surrogate markers for Micro- and Macro-vascular 
hard endpoints for Innovative diabetes Tools) project 
to further explore genetic markers for diabetes com-
plications. For both of these efforts, JDRF joined IMI 
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at an early stage and played an essential role in setting  
the agenda and the terms for the call for proposals. For 
example, the foundation jointly organized a workshop 
with IMI called the “Patient Diabetes Focus Meeting” 
to explore R&D gaps in the diabetes area from the 
perspective of patient needs and challenges. This 2014 
meeting triggered in-depth discussions between JDRF 
and IMI, leading to the participation of JDRF as an 
Associate Partner to IMI and co-coordinator/co- 
founder of the IMI 2 topic “Translational Approaches 
to Disease Modifying Therapy of Type 1 Diabetes 
Mellitus”. This seven-year project would create a 
comprehensive interdisciplinary network of clinical 
and basic scientists in cooperation with pharmaceuti-
cal companies and other non-profit organizations to 
advance the prediction, staging, prevention, and ar-
rest-of-progression of type 1 diabetes. The concept 
aims to create novel tools such as biomarkers, disease 
models, and clinical trial paradigms, all of which are 
currently under review with a plan to start in Septem-
ber 2015. In addition, a Patient Advisory Committee 
will be an integral component embedded in the part-
nership to ensure that the desires and needs of patients 
and their families are addressed throughout the pro-
gram. Furthermore, JDRF is in active discussions with 
IMI and EFPIA partners on ongoing and upcoming 
initiatives aimed at understanding cause and progres-
sion of T1D and delivering next generation therapeu-
tics. These include areas of diabetic kidney disease, 
encapsulation of insulin-producing cells and modula-
tion of gut microbiome, in full alignment with the 
foundation’s core mission to deliver life-changing 
therapies for individuals with T1D. 
5. Conclusion 
Disease-focused philanthropic organizations are es-
sential thought-leaders with a unique stake in drug 
development. Foundations are in a unique position to 
coordinate both the patient and research communities 
in focused efforts that generate research findings for 
the entire community, a value proposition that goes 
beyond their ability to provide additional funding. As 
non-profit organizations with missions to improve the 
lives of their patient populations, the majority is not 
beholden to a specific product and they can leverage 
their neutral convening ability to bring together com-
peting companies and regulatory scientists to address 
broad challenges in their disease or condition of inter-
est. However as with other stakeholders, their ability 
to provide financial resources and dedicate subject 
matter expertise to research is also limited, and many 
have found opportunities to expand their impact by 
leading and participating in public–private partner-
ships such as research consortia. Ensuring that the 
entire research community benefits from the collective 
expertise, coordination of resources, and distribution 
of results raises the tide for all boats, a central prin-
ciple shared by both research consortia and dis-
ease-focused foundations. 
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